P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T...

por Facon, T., Kumar, S. K., Plesner, T., Moreau, P., Bahlis, N., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Borgsten, F., Usmani, S. Z.
Publicado 2022

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...

por Weisel, K., Kumar, S., Moreau, P., Bahlis, N., Facon, T., Plesner, T., Orlowski, R., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C., Raje, N., Tiab1, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Krevvata, M, Carson, R, Borgsten, F., Usmani, S.
Publicado 2023